GERMANTOWN, Md., Sept. 24,
2015 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a
biopharmaceutical company using neural stem cell technology to
develop small molecule and cell therapy treatments for central
nervous system diseases, announced that principal investigator,
Eva Feldman, MD, PhD, will give an
update on NSI-566 Phase I and Phase II trial data in amyotrophic
lateral sclerosis (ALS) at the American Neurological Association
Annual Meeting in Chicago, Il on
Monday, September 28, 2015.
Dr. Feldman will review the current state of cell-based
therapies being studied for the treatment of neurological
disorders, including Neuralstem's NSI-566, an investigational
spinal cord-derived stem cell therapy in development for ALS, in
"The Current State of Stem Cell Therapies" session. The Phase I and
II trials are the first in the world to use intraspinal stem cell
transplantation. She will also discuss NSI-532.IGF, Neuralstem's
next-generation cell therapy for Alzheimer's disease, at the
meeting as part of the "Dementia and Aging" special interest group
symposium. Dr. Feldman is Director of the A. Alfred Taubman Medical
Research Institute and Director of Research of the ALS Clinic at
the University of Michigan Health
System, and an unpaid consultant to Neuralstem.
Dr. Feldman will appear within the following ANA
sessions:
Interactive Lunch Workshop: Current State of Stem Cell
Therapies
Monday, September 28,
2015 - 11:45am to 1:00pm
Special Interest Group Symposia 3: Dementia and
Aging
Monday, September 28,
2015 - 3:30pm to 5:30pm
- Data Blitz Presentation featuring Dr. Feldman (5:20 –
5:30 pm): Human Neural
Stem Cells Expressing IGF-1: A Novel Cellular Therapy for
Alzheimer's Disease
About Neuralstem
Neuralstem's patented technology enables the commercial-scale
production of multiple types of central nervous system stem cells,
which are under development for the potential treatment of central
nervous system diseases and conditions.
Neuralstem's ability to generate human neural stem cell lines
for chemical screening has led to the discovery and patenting of
compounds that Neuralstem believes may stimulate the brain's
capacity to generate neurons, potentially reversing pathologies
associated with certain central nervous system (CNS) conditions.
The company has completed Phase Ia and Ib trials evaluating
NSI-189, its first neurogenic small molecule product candidate, for
the treatment of major depressive disorder (MDD), and is expecting
to initiate a Phase II study for MDD and a Phase Ib study for
cognitive deficit in schizophrenia in 2015.
Neuralstem's first stem cell product candidate, NSI-566, a
spinal cord-derived neural stem cell line, is under development for
treatment of amyotrophic lateral sclerosis (ALS). Neuralstem has
completed two clinical studies, in a total of thirty patients,
which met primary safety endpoints. In addition to ALS, NSI-566 is
also in a Phase I trial in chronic spinal cord injury at UC San
Diego School of Medicine, as well as in clinical development to
treat ischemic stroke.
Neuralstem's next generation stem cell product, NSI-532.IGF,
consists of human cortex-derived neural stem cells that have been
engineered to secrete human insulin-like growth factor 1 (IGF-1).
In animal data presented at the Congress of Neurological Surgeons
2014 Annual Meeting, the cells rescued spatial learning and memory
deficits in an animal model of Alzheimer's disease.
For more information, please visit www.neuralstem.com or connect
with us on Twitter, Facebook and LinkedIn.
Cautionary Statement Regarding Forward Looking Information:
This news release contains "forward-looking statements" made
pursuant to the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements
relate to future, not past, events and may often be identified by
words such as "expect," "anticipate," "intend," "plan," "believe,"
"seek" or "will." Forward-looking statements by their nature
address matters that are, to different degrees, uncertain. Specific
risks and uncertainties that could cause our actual results to
differ materially from those expressed in our forward-looking
statements include risks inherent in the development and
commercialization of potential products, uncertainty of clinical
trial results or regulatory approvals or clearances, need for
future capital, dependence upon collaborators and maintenance of
our intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking
statements. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed
from time to time in Neuralstem's periodic reports, including the
Annual Report on Form 10-K for the year ended December 31, 2014, and Form 10-Q for the three
and six months ended June 30, 2015,
filed with the Securities and Exchange Commission (SEC), and in
other reports filed with the SEC.
![Neuralstem Logo. Neuralstem Logo.](http://photos.prnewswire.com/prnvar/20061221/DCTH007LOGO)
Logo -
http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/neuralstem-investigator-to-provide-update-on-als-and-alzheimers-at-american-neurological-association-annual-meeting-300148430.html
SOURCE Neuralstem, Inc.